Covid vaccines are once again on the agenda for the Centers for Disease Control and Prevention’s vaccine advisory panel.

Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

An interim analysis of safety data showed no increased risk associated with Pfizer’s respiratory syncytial virus vaccine when ...

By Ahmed Aboulenein WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...

In August last year, the Health Department cut around $500 million in mRNA research funding, with Health Secretary Robert F.

Following a difficult year that saw Ixchiq’s license suspended in the US, Valneva is pinning hopes on upcoming pipeline ...

Pfizer targets 2028 for its first obesity drug approval Company plans to advance more than 20 obesity trials in 2026 RSV vaccine quarterly sales top expectations Feb 3 (Reuters) - Pfizer (PFE.N), ...

Pfizer’s Albert Bourla put it more bluntly in Davos last month, saying it’s a “different world when you start discussing ...

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...